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CHAPTER I 
1.INTRODUCTION 
1.1 CANCER 
Cancer is a diseases involving abnormal cell growth with the 
potential to invade or spread to other parts of the body . [1]&[2] Not all 
tumors are cancerous; benign tumors do not spread to other parts 
of the body . [2] Possible signs and symptoms include a lump, 
abnormal bleeding, prolonged cough, unexplained weight loss and 
a change in bowel movements. While these symptoms may indicate 
cancer, they may have other causes . [3] Over 100 cancers affect 
humans . [2]  
Many cancers can be prevented by not smoking, maintaining a 
healthy weight, not drinking too much alcohol, eating plenty of 
vegetables, fruits and whole grains,  vaccination against certain 
infectious diseases, not eating too much processed and red meat, 
and avoiding too much sunlight exposure . [9]&[10] Early detection 
through screening is useful for cervical and colorectal 
cancer . [11] The benefits of screening in breast cancer are 
controversial. [11]&[12] Cancer is often treated with some combination 
of radiation therapy, surgery, chemotherapy, and targeted 
therapy. [1]&[13] Pain and symptom management are an important 
part of care. Palliative care is particularly important in people with 
advanced disease. [1] The chance of survival depends on the type of 
cancer and extent of disease at the start of treatment. [6] In children 
under 15 at diagnosis the five-year survival rate in the developed 
world is on average 80%. [14]  For cancer in the United States the 
average five-year survival rate is 66%. [15] 
Worldwide approximately 18% of cancer deaths are related 
to infectious diseases. This proportion ranges from a high of 25% 
in Africa to less than 10% in the developed world . [5] Viruses are the 
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usual infectious agents that cause cancer but  cancer 
bacteria and parasites may also play a role. 
In 2012 about 14.1 million new cases of cancer occurred globally 
(not including skin cancer other than melanoma). [6] It caused about 
8.2 million deaths or 14.6% of  human deaths. [6]&[16] The most 
common types of cancer in males are lung cancer, prostate 
cancer, colorectal cancer and stomach cancer. In females, the 
most common types are breast cancer, colorectal cancer, lung 
cancer and cervical cancer . [6] If skin cancer other 
than melanoma were included in total new cancers each year it 
would account for around 40% of cases. [17]&[18] In children, acute 
lymphoblastic leukaemia and brain tumors are most common 
except in Africa where non-Hodgkin lymphoma occurs more 
often. [14] In 2012, about 165,000 children under 15 years of age 
were diagnosed with cancer. The risk of cancer increases 
significantly with age and many cancers occur more commonly 
in developed countries. [6] Rates are increasing as more people live 
to an old age and as lifestyle changes occur in the developing 
world. [19] The financial costs of cancer were estimated at $1.16 
trillion US dollars per year as of 2010. [20] 
Cancers are a large family of diseases that involve abnormal  cell 
growth with the potential to invade or spread to other parts of the 
body. [1]&[2] They form a subset of neoplasms. A neoplasm or tumor 
is a group of cells that have undergone unregulated growth and will 
often form a mass or lump, but may be distributed d iffusely. [21][22] 
All tumor cells show the six hallmarks of cancer. These 
characteristics are required to produce a malignant tumor. They 
include: [23] 
 Cell growth and division absent the proper signals 
 Continuous growth and division even given contrary signals  
 Avoidance of programmed cell death 
 Limitless number of cell divisions 
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 Promoting blood vessel construction 
 Invasion of tissue and formation of  metastases[24] 
The progression from normal cells to cells that can form a 
detectable mass to outright cancer involves multiple steps known 
as malignant progression. [24]&[25] 
When cancer begins, it produces no symptoms. Signs and 
symptoms appear as the mass grows or ulcerates. The findings 
that result depend on the cancer's type and location. Few 
symptoms are specific. Many frequently occur in individuals who 
have other conditions. Cancer is a "great imitator". Thus, it is 
common for people diagnosed with cancer to have been treated for 
other diseases, which were hypothesized to be causing their 
symptoms. [26] 
People may become anxious or depressed post -diagnosis. The risk 
of suicide in people with cancer is approximately double . [27] 
Local symptoms may occur due to the mass of the tumor or its 
ulceration. For example, mass effects from lung cancer can block 
the bronchus resultingin cough or pneumonia; esophagealcancer  
can cause narrowing of the esophagus, making it difficult or painful 
to swallow; and colorectal cancer may lead to narrowing or 
blockages in the bowel, affecting bowel habits. Masses in breasts 
or testicles may produce observable lumps.  Ulceration can cause 
bleeding that, if it occurs in the lung, will lead to  coughing up 
blood, in the bowels to anemia or rectal bleeding, in the bladder 
to blood in the urine and in the uterus to vaginal bleeding. Although 
localized pain may occur in advanced cancer, the initial swelling is 
usually painless. Some cancers can cause a buildup of fluid within 
the chest or abdomen . [26] 
 
1.1.2Systemic symptoms 
General symptoms occur due to effects that are not related to 
direct or metastatic spread. These may include:  unintentional 
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weight loss, fever. [28] Hodgkin disease,leukemia and cancers of the 
liver or kidney can cause a persistent fever. [26] 
Some cancers may cause specific groups of systemic symptoms, 
termed paraneoplastic phenomena. [26] 
 
1.1.2.3 Mechanism Of Cancer Cell Formation And Spreading 
Cancer can spread from its original site by local spread, lymphatic 
spread to regional lymph nodes or by hematogenous spread via the 
blood to distant sites, known as metastasis. When cancer spreads 
by a hematogenous route, it usually spreads all over the body. 
However, cancer 'seeds' grow in certain selected site only ('soil') 
as hypothesized in the soil and seed hypothesis of cancer 
metastasis. The symptoms of metastatic cancers depend on the 
tumor location and can include enlarged lymph nodes (which can 
be felt or sometimes seen under the skin and are typically 
hard), enlarged liver or enlarged spleen, which can be felt in 
the abdomen, pain or fracture of affected bones 
and neurological symptoms. [26] 
 
1.2 Causes 
The majority of cancers, some 90–95% of cases, are due 
to environmental factors. The remaining 5–10% are due 
to inherited genetics. Environmental, as used by cancer 
researchers, means any cause that is not  inherited genetically, 
such as lifestyle, economic and behavioral factors and not 
merely pollution . [29] Common environmental factors that contribute 
to cancer death include tobacco (25–30%), diet and obesity (30–
35%), infections (15–20%), radiation, stress.   
Tobacco use is the cause of about 22% of cancer deaths . [1] Another 
10% is due to obesity, poor diet, lack of physical activity and 
drinking alcohol . [1]&[4] Other factors include certain infections, 
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exposure to ionizing radiation and environmental pollutants . [5] It is  
due to infections such as hepatitis B, hepatitis C and human 
papillomavirus (HPV). [1] These factors act, at least partly, by 
changing the genes of a cell. Typically many genetic changes are 
required before cancer develops. [6] Approximately 5–10% of 
cancers are due to inherited genetic defects from a person's 
parents. [7] Cancer can be detected by certain signs and symptoms 
or screening tests. [1] It is then typically further investigated 
by medical imaging and confirmed by biopsy. [8] 
 
It is not generally possible to prove what caused a particular 
cancer because the various causes do not have specific 
fingerprints. For example, if a person who uses tobacco heavily 
develops lung cancer, then it was probably caused by the tobacco 
use, but since everyone has a small chance of developing lung 
cancer as a result of air pollution or radiation, the cancer may have 
developed for one of those reasons. Excepting the rare 
transmissions that occur with pregnancies and occasional  organ 
donors, cancer is generally not a transmissible disease. [30] 
 
1.21 Chemicals 
Figure No.1: Lag time between Smoking and Lung Cancer 
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The incidence of lung cancer is highly correlated with smoking. 
Exposure to particular substances have been linked to specific 
types of cancer. These substances are called  carcinogens. 
Tobacco smoke, for example, causes 90% of  lung cancer. [31] It also 
causes cancer in the larynx, head, neck, stomach, bladder, 
kidney, esophagus and pancreas. [32] Tobacco smoke contains over 
fifty known carcinogens, including nitrosamines and polycyclic 
aromatic hydrocarbons. [33] 
Tobacco is responsible about one in f ive cancer deaths worldwide  
[33] and about one in three in the developed world . [34].Lung cancer 
death rates in US have  mirrored smoking patterns, with increases 
in smoking followed by dramatic increases in lung cancer death 
rates and, more recently, decreases in smoking rates since the 
1950s followed by decreases in lung cancer death rates in men 
since 1990. [35]&[36] 
In Western Europe, 10% of cancers in males and 3% of cancers in 
females are attributed to alcohol exposure, especially liver and 
digestive tract cancers . [37] Cancer from work-related substance 
exposures may cause between 2 and 20% of cases,  [38] causing at 
least 200,000 deaths. Cancers such as lung 
cancer and mesothelioma can come from inhaling tobacco smoke 
or asbestos fibers, or leukemia from exposure to benzene . [39]  
 
1.2.2 Life style Changes 
Diet, physical inactivity and obesity are related to up to 30–35% of 
cancer deaths . [5] [40] In the United States excess body weight is 
associated with the development of many types of cancer and is a 
factor in 14–20% of cancer deaths . [40] A UK study including data on 
over 5 million people showed higher body mass index to be related 
to at least 10 types of cancer and responsible for around 12,000 
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cases each year in that country . [41] Physical inactivity is believed to 
contribute to cancer risk, not only through its effect on body weight 
and also through negative effects on the immune 
system and endocrine system. More than half of the effect from 
diet is due to overnutrition (eating too much), rather than from 
eating too few vegetables or other healthful foods.  
Some specific foods are linked to specific cancers. A high-salt diet 
is linked to gastric cancer . [42] Aflatoxin B1, a frequent food 
contaminant, causes liver cancer.  Betel nut chewing can cause oral 
cancer . [42] National differences in dietary practices may partly 
explain differences in cancer incidence. For example,  gastric 
cancer is more common in Japan due to its high-salt 
diet while colon cancer is more common in the United States. 
Immigrant cancer profiles develop mirror that of their new country, 
often within one generation. [44] 
 
1.2.3. Infection 
Oncoviruses (viruses that can cause cancer) include human 
papillomavirus (cervical cancer), Epstein–Barr virus (B-cell 
lymphoproliferativedisease and nasopharyngealcarcinoma), Kaposi'
s sarcoma herpesvirus (Kaposi's sarcoma and primary effusion 
lymphomas), hepatitis B and hepatitis C viruses (hepatocellular 
carcinoma) and human T-cell leukemia virus-1 (T-cell leukemias). 
 
1.2.4. Radiation 
Up to 10% of invasive cancers are related to radiation exposure, 
including both ionizing radiation and non-ionizing ultraviolet 
radiation.[5] Additionally, the majority of non-invasive cancers are 
non-melanoma skin cancers caused by non-ionizing ultraviolet 
radiation, mostly from sunlight. Sources of ionizing radiation 
include medical imaging and radon gas. 
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Ionizing radiation is not a particularly 
strong mutagen.[48] Residential exposure to radon gas, for 
example, has similar cancer risks as passive smoking. Radiation is 
a more potent source of cancer when combined with other cancer-
causing agents, such as radon plus tobacco smoke.  Radiation can 
cause cancer in most parts of the body, in all animals and at any 
age.. 
Medical use of ionizing radiation have small growing source of 
radiation-induced cancers. Ionizing radiation may be used to treat 
other cancers, but this may, in some cases, induce a second form 
of cancer . [48] It is also used in some kinds of  medical imaging. [49] 
Prolonged exposure to ultraviolet radiation from the sun can lead 
to melanoma and other skin malignancies.  Clear evidence 
establishes ultraviolet radiation, especially the non -ionizing 
medium wave UVB, as the cause of most non-melanoma skin 
cancers, which are the most common forms of cancer in the 
world. [50] 
Non-ionizing radio frequency radiation from mobile phones, electric 
power transmission and other similar sources have been described 
as a possible carcinogen by the World Health 
Organization's International Agency for Research on 
Cancer. [51] However, studies have not found a consistent link 
between mobile phone radiation and cancer risk. [52] 
Some substances cause cancer primarily through their  chemical 
rather than physical, effects. A prominent example of this is 
prolonged exposure to asbestos, naturally occurring mineral fibers 
that are a major cause of  mesothelioma (cancer of the serous 
membrane) usually the serous membrane surrounding the 
lungs. Other substances in this category, including both naturally 
occurring and synthetic asbestos-like fibers, such 
as wollastonite, attapulgite, glass wool and rock wool, are believed 
metallic cobalt and nickel and crystallinesilica (quartz, cristobalite 
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and tridymite). Usually, physical carcinogens must get inside the 
body (such as through inhalation) and require years of exposure to 
produce cancer.[55] Children and adolescents are twice as likely to 
develop radiation-induced leukemia as adults; radiation exposure 
before birth has ten times the effect  
Physical trauma resulting in cancer is relatively  rare. Claims that 
breaking bones resulted in bone cancer, for example, have not 
been proven. Similarly, physical trauma is not accepted as a cause 
for cervical cancer, breast cancer or brain cancer.  One accepted 
source is frequent, long-term application of hot objects to the body. 
It is possible that repeated burns on the same part of the body, 
such as those produced by kanger and kairo heaters 
(charcoal hand warmers), may produce skin cancer, especially if 
carcinogenic chemicals are also present.  Frequent consumption of 
scalding hot tea may produce esophageal cancer. [56] Generally, it is 
believed that cancer arises, or a pre-existing cancer is 
encouraged, during the process of healing, rather than directly by 
the trauma. However, repeated injuries to the same tissues might 
promote excessive cel l proliferation, which could then increase the 
odds of a cancerous mutation. [56] 
Chronic inflammation has been hypothesized to directly cause 
mutation. [56][57] Inflammation can contribute to proliferation, 
survival, angiogenesis and migration of cancer cells by influencing 
the tumor microenvironment. [58]&[59] Oncogenes build up an 
inflammatory pro-tumorigenic microenvironment. [60] 
 
1.2.5 Hormones 
Some hormones play a role in the development of cancer by 
promoting cell proliferation. [61] Insulin-like growth factors and their 
binding proteins play a key role in cancer cell proliferation, 
differentiation, apoptosis, suggesting possible involvement in 
carcinogenesis. [62] 
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Hormones are important agents in sex-related cancers, such as 
cancer of the breast, endometrium, prostate, ovary, testis and also 
of thyroid cancer and bone cancer. For example, the daughters of 
women who have breast cancer have signif icantly higher levels 
of estrogen and progesterone than the daughters of women without 
breast cancer. These higher hormone levels may explain their 
higher risk of breast cancer, even in the absence of a breast -
cancer gene. Similarly, men of African ancestry have significantly 
higher levels of testosterone than men of European ancestry and 
have a correspondingly higher level of prostate cancer.  Men of 
Asian ancestry, with the lowest levels of testosterone -
activating androstanediolglucuronide, have the lowest levels of 
prostate cancer. [61] 
Other factors are relevant: obese people have higher levels of 
some hormones associated with cancer and a higher rate of those 
cancers. Women who take hormone replacement therapy have  
higher risk of developing cancers associated with those 
hormones. On the other hand, people who exercise far more than 
average have lower levels of these hormones and lower risk of 
cancer. Osteosarcoma may be promoted by growth 
hormones. Some treatments and prevention approaches leverage 
this cause by artif icially reducing hormone levels and thus 
discouraging hormone-sensitive cancers. [61] Cancer is 
fundamentally  disease of tissue growth regulation. In order for a 
normal cell to transform into a cancer cell, the genes that regulate 
cell growth and differentiation must be altered. [65] 
The affected genes are divided into two broad 
categories. Oncogenes are genes that promote cell growth and 
reproduction. Tumor suppressor genes are genes that inhibit cell 
division and survival. Malignant transformation can occur through 
the formation of novel oncogenes, the inappropriate over -
expression of normal oncogenes, or by the under -expression or 
disabling of tumor suppressor genes. Typically, changes in multiple 
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genes are required to transform a normal cell into a cancer 
cell.[66] 
Genetic changes can occur by different mechanisms. The gain or 
loss of an entire chromosome can occur through errors in mitosis. 
More common are mutations, which are changes in 
the nucleotide sequence of genomic DNA. 
Large-scale mutations involve the deletion or gain of a portion of a  
chromosome. Genomic amplification occurs when a cell gains 
copies (often 20 or more) of a small chromosomal locus, usually 
containing one or more oncogenes and adjacent genetic 
material. Translocation occurs when two separate chromosomal 
regions become abnormally fused, often at a characteristic 
location. A well-known example of this is the Philadelphia 
chromosome, or translocation of chromosomes 9 and 22, which 
occurs in chronic myelogenous leukemia and results in production 
of the BCR-abl fusion protein, an oncogenic tyrosine kinase. 
Small-scale mutations include point mutations, deletions, and 
insertions, which are in the promoter region of a gene and affect 
its expression, or may occur in the gene's coding sequence and 
alter the function or stability of its  protein product. Disruption of a 
single gene may also result from integration of genomic 
material from a DNA virus or retrovirus, leading to the expression 
of viral oncogenes in the affected cell and its descendants.  
Replication of the data contained within the DNA of living cells 
will probabilistically result in some errors (mutations). Complex 
error correction and prevention is built into the process and 
safeguards the cell against cancer. If a significant error occurs, the 
damaged cell can self-destruct through programmed cell death, 
termed apoptosis. If the error control processes fail, then the 
mutations will survive and be passed along to  daughter cells. 
Some environments make errors more likely to arise and 
propagate. Such environments can include the presence of 
12 
 
disruptive substances called carcinogens, repeated physical injury, 
heat, ionising radiation or hypoxia. [67] 
The errors that cause cancer are self -amplifying and compounding, 
for example: 
 A mutation in the error-correcting machinery of a cell might cause 
that cell and its children to accumulate errors more rapidly.  
 A further mutation in an oncogene might cause the cell to 
reproduce more rapidly and more frequently than its normal 
counterparts. 
 A further mutation may cause loss of a tumor suppressor gene, 
disrupting the apoptosis signaling pathway and immortalizing the 
cell. 
 A further mutation in the signaling machinery of the cell might send 
error-causing signals to nearby cells.  
 
The transformation of a normal cell into cancer is akin to a  chain 
reaction caused by initial errors, which compound into more severe 
errors, each progressively allowing the cell to escape more controls 
that limit normal tissue growth. This rebellion -like scenario is an 
undesirable survival of the f ittest, where the driving forces 
of evolution work against the body's design and enforcement of 
order. Once cancer has begun to develop, this ongoing process, 
termed clonal evolution, drives progression towards more 
invasive stages.[68] Clonal evolution leads to intra-tumour 
heterogeneity (cancer cells with heterogeneous mutations) that 
complicates designing effective treatment strategies  
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Figure No:2  Cell Proliferation 
 
 
. 
Characteristic abilities developed by cancers are divided into 
categories, specifically evasion of apoptosis, self -sufficiency in 
growth signals, insensitivity to anti -growth signals, sustained 
angiogenesis, limitless replicative potential, metastasis, 
reprogramming of energy metabolism and evasion of immune 
destruction. [24]&[25] 
The classical view of cancer is a set of diseases that are driven by 
progressive genetic abnormalities that include mutations in tumor -
suppressor genes and oncogenes and chromosomal abnormalities. 
Later epigenetic alterations' role was identified. [69] 
Epigenetic alterations refer to functionally relevant modifications to 
the genome that do not change the nucleotide sequence. Examples 
of such modifications are changes in  DNA 
methylation (hypermethylation and hypomethylation),  histone 
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modification[70] and changes in chromosomal architecture (caused 
by inappropriate expression of proteins such 
as HMGA2 or HMGA1). [71]  Each of these alterations regulates gene 
expression without altering the underlying DNA sequence. These 
changes may remain through cell divisions, last for multiple 
generations and can be considered to be epimutations (equivalent 
to mutations). 
Epigenetic alterations occur frequently in cancers. As an example, 
one study listed protein coding genes that were frequently altered 
in their methylation in association with colon cancer. These 
included 147 hypermethylated and 27 hypomethylated genes. Of 
the hypermethylated genes, 10 were hypermethylated in 100% of 
colon cancers and many others were hypermethylated in more than 
50% of colon cancers. [72] 
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Figure No:3 
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While epigenetic alterations are found in cancers, the epigenetic 
alterations in DNA repair genes, causing reduced expression of 
DNA repair proteins, may be of particular importance. Such 
alterations are thought to occur early in progression to cancer and 
to be a likely cause of the genetic instability characteristic of 
cancers. [73], [74], [75]&[76] 
Reduced expression of DNA repair genes disrupts DNA repair. This 
is shown in the figure at the 4th level from the top. (In the figure, 
red wording indicates the central role of DNA damage and defects 
in DNA repair in progression to cancer.) When DNA repair is 
deficient DNA damage remains in cells at a higher than usual level 
(5th level) and cause increased frequencies of mutation and/or 
epimutation (6th level). Mutation rates increase substantially in 
cells defective in DNA mismatch repair [77]&[78] or in homologous 
recombinational repair (HRR). [79]  Chromosomal rearrangements 
and aneuploidy also increase in HRR defective cells. [80] 
Higher levels of DNA damage cause increased mutation (ri ght side 
of figure) and increased epimutation. During repair of DNA double 
strand breaks, or repair of other DNA damage, incompletely 
cleared repair sites can cause epigenetic gene silencing. [81][82] 
Deficient expression of DNA repair proteins due to an inherited 
mutation can increase cancer risks. Individuals with an inherited 
impairment in any of 34 DNA repair genes (see article  DNA repair-
deficiency disorder) have increased cancer risk, with some defects 
ensuring a 100% lifetime chance of cancer (e.g. p53 
mutations). [83] Germ line DNA repair mutations are noted on the 
figure's left side. However, such germline mutations (which cause 
highly penetrant cancer syndromes) are the cause of only about 1 
percent of cancers. [84] 
In sporadic cancers, deficiencies in DNA repair are occasionally 
caused by a mutation in a DNA repair gene but are much more 
frequently caused by epigenetic alterations that reduce or silence 
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expression of DNA repair genes. This is indicated in the figure at 
the 3rd level. Many studies of heavy metal -induced carcinogenesis 
show that such heavy metals cause a reduction in expression of 
DNA repair enzymes, some through epigenetic mechanisms. DNA 
repair inhibition is proposed to be a predominant mechanism in 
heavy metal-induced carcinogenicity. In addition, frequent 
epigenetic alterations of the DNA sequences code for small RNAs 
called microRNAs (or miRNAs). miRNAs do not code for proteins, 
but can "target" protein-coding genes and reduce their expression.  
Cancers usually arise from an assemblage of mutations and 
epimutations that confer a selective advantage leading to clonal 
expansion. [85] 
Cancer is becoming a high profile disease in developed and 
developing worlds. In 2007 the WHO published that in 2005, 7.6 
million people died from cancer related diseases with the majority 
of these people living in low-income countries . In the United 
States cancer is the cause of 1 in 4 deaths and in 2010 it was 
estimated there were over 1.5 million new cases of cancer  . Cancer 
Research UK said in 2012 14.1 mill ion adults were diagnosed with 
cancer and 8.2 million people were killed by cancer globally  . 
Therefore, the demand for a cure and the prevention of cancer is 
extremely high. 
 
1.2.6. Dietary 
While many dietary recommendations have been proposed to 
reduce cancer risks, the evidence to support them is not 
definitive . [9]&[93]  The primary dietary factors that increase risk 
are obesity and alcohol consumption. Diets low in fruits and 
vegetables and high in red meat have been implicated but reviews 
and meta-analyses do not come to a consistent conclusion.  [94]&[95] 
 A 2014 meta-analysis f ind no relationship between fruits and 
vegetables and cancer. [96]   Coffee is associated with a reduced risk 
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of liver cancer. [97]  Studies have linked excess consumption of red 
or processed meat to an increased risk of breast cancer,  colon 
cancer and pancreatic cancer, a phenomenon that could be due to 
the presence of carcinogens in meats cooked at high temperatures.  
[98]&[99] In 2015 the IARC reported that eating processed meat (e.g., 
bacon, ham, hot dogs, sausages) and, to a lesser degree, red 
meat was linked to some cancers. [100]&[101] Dietary 
recommendations for cancer prevention typically include an 
emphasis on vegetables, fruit, whole grains and fish and an 
avoidance of processed and red meat (beef, pork, lamb), animal 
fats and refined carbohydrates. [9]&[93] 
 
1.2.7. Medication 
Medications can be used to prevent cancer in a few 
circumstances. [102]  In the general population,  NSAIDs reduce the 
risk of colorectal cancer; however, due to cardiovascular and 
gastrointestinal side effects, they cause overall harm when used 
for prevention. [103]  Aspirin has been found to reduce the risk of 
death from cancer by about 7%. [104] COX-2 inhibitors may 
decrease the rate of polyp formation in people with familial 
adenomatous polyposis; however, it is associated with the same 
adverse effects as NSAIDs. [105]   Daily use 
of tamoxifen or raloxifene reduce the risk of breast cancer in high-
risk women. [106]  The benefit versus harm for 5-alpha-reductase 
inhibitor such as finasteride is not clear. [107] 
Vitamins are not effective at preventing cancer, [108] although low 
blood levels of vitamin D are correlated with increased cancer 
risk. [109]&[110]  People who have cancer are also at a high risk of 
developing vitamin D deficiency. [111]  Whether this relationship is 
causal and vitamin D supplementation is protective is not 
determined. [112]  Beta-carotene supplementation increases lung 
cancer rates in those who are high risk. [113] Folic 
acid supplementation is not effective in preventing colon cancer 
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and may increase colon polyps. [114] It is unclear if selenium 
supplementation has an effect. [115] 
 
1.2.8. Vaccination 
Vaccines have been developed that prevent infection by 
some carcinogenic viruses.  Human papillomavirus 
vaccine (Gardasil and Cervarix) decrease the risk of 
developing cervical cancer.  The hepatitis B vaccine prevents 
infection with hepatitis B virus and thus decreases the risk of liver 
cancer. [116]  The administration of human papillomavirus and 
hepatitis B vaccinations is recommended when resources allow. [117] 
 
1.2.9. Screening 
Unlike diagnostic efforts prompted by symptoms and medical signs, 
cancer screening involves efforts to detect cancer after it has 
formed, but before any noticeable symptoms appear.  This may 
involve physical examination, blood or urine tests or medical 
imaging. [118] 
Cancer screening is not available for many types of cancers. E ven 
when tests are available, they may not be recommended for 
everyone. Universal screening or mass screening involves 
screening everyone. [119] Selective screening identifies people who 
are at higher risk, such as people with a family history. Several 
factors are considered to determine whether the benefits of 
screening outweigh the risks and the costs of screening. [118] These 
factors include: 
 Possible harms from the screening test: for example, X-ray images 
involve exposure to potentially harmful  ionizing radiation 
 The likelihood of the test correctly identifying cancer  
 The likelihood that cancer is present: Screening is not normally 
useful for rare cancers. 
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 Possible harms from follow-up procedures 
 Whether suitable treatment is available 
 Whether early detection improves treatment outcomes 
 Whether the cancer will ever need treatment 
 Whether the test is acceptable to the people: If a screening test is 
too burdensome (for example, extremely painful), then people will 
refuse to participate. [119] 
 Cost 
 
1.3 Diagnosis 
Unlike diagnostic efforts prompted by symptoms and medical signs, 
cancer screening involves efforts to detect cancer after it has 
formed, but before any noticeable symptoms appear.  This may 
involve physical examination, blood or urine tests or medical 
imaging. 
Cancer screening is not available for many types of cancers. Even 
when tests are available, they may not be recommended for 
everyone. Universal screening or mass screening involves 
screening everyone. Selective screening identifies people who are 
at higher risk, such as people with a family history. Several factors 
are considered to determine whether the benefits of screening 
outweigh the risks and the costs of screening.  These factors 
include: 
 Possible harms from the screening test: for example, X-ray images 
involve exposure to potentially harmful  ionizing radiation 
 The likelihood of the test correctly identifying cancer  
 The likelihood that cancer is present: Screening is not normally 
useful for rare cancers. 
 Possible harms from follow-up procedures 
 Whether suitable treatment is available 
 Whether early detection improves treatment outcomes 
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 Whether the cancer will ever need treatment  
 Whether the test is acceptable to the people: If a screening test is 
too burdensome (for example, extremely painful), then people will 
refuse to participate 
 
Chemically-derived drugs have been developed and other cancer 
treatments pre-exist . However, current methods such as 
chemotherapy have their limitations due to their toxic effects on 
non-targeted tissues furthering human health problems . Therefore, 
there is a demand for alternative treatments with naturally -derived 
anticancer agents with plants being the desired source. 
 
1.4 Prevention 
Cancer prevention is defined as active measures to decrease 
cancer risk. The vast majority of cancer cases are due to 
environmental risk factors. Many of these environmental factors 
are controllable lifestyle choices. Thus, cancer is generally 
preventable. Between 70% and 90% of common cancers are due to 
environmental factors and therefore potentially preventable. [91] 
Greater than 30% of cancer deaths could be prevented by avoiding 
risk factors including: tobacco, excess weight/obesity, insufficient 
diet, physical inactivity, alcohol, sexually transmitted 
infections and air pollution. Not all environmental causes are 
controllable, such as naturally occurring background radiation and 
cancers caused through hereditary genetic disorders and thus are 
not preventable via personal behavior.  
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1.5. Classification 
Cancers are classified by the type of cell that the tumor cells 
resemble and is therefore presumed to be the orig in of the tumor. 
These types include: 
 Carcinoma: Cancers derived from epithelial cells. This group 
includes many of the most common cancers and include nearly all 
those in the breast, prostate, lung, pancreas and colon. 
 Sarcoma: Cancers arising from connective 
tissue (i.e. bone, cartilage, fat, nerve), each of which develops 
from cells originating in mesenchymal cells outside the bone 
marrow. 
 Lymphoma and leukemia: These two classes arise from 
hematopoietic (blood-forming) cells that leave the marrow and tend 
to mature in the lymph nodes and blood, respectively. [88] 
 Germ cell tumor: Cancers derived from pluripotent cells, most often 
presenting in the testicle or 
the ovary (seminoma and dysgerminoma, respectively). 
 Blastoma: Cancers derived from immature "precursor" cells or 
embryonic tissue. 
 
Cancers are usually named using -carcinoma, -sarcoma or -
blastoma as a suffix, with the Latin or Greek word for the  organ or 
tissue of origin as the root. For example, cancers of the 
liver parenchyma arising from malignant epithelial cells is 
called hepatocarcinoma, while a malignancy arising from primitive 
liver precursor cells is called a hepatoblastoma and a cancer 
arising from fat cells is called a liposarcoma. For some common 
cancers, the English organ name is used. For example, the most 
common type of breast cancer is called ductal carcinoma of the 
breast. Here, the adjective ductal refers to the appearance of 
cancer under the microscope, which suggests that it has originated 
in the milk ducts. 
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Benign tumors (which are not cancers) are named using -oma as a 
suffix with the organ name as the root. For example, a benign 
tumor of smooth muscle cells is called a  leiomyoma (the common 
name of this frequently occurring benign tumor in the uterus 
is fibroid). Confusingly, some types of cancer use the -noma suffix, 
examples including melanoma and seminoma. 
Some types of cancer are named for the size and shape of the 
cells under a microscope, such as giant cell carcinoma, spindle cell 
carcinoma and small-cell carcinoma. 
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CHAPTER II 
2. REVIEW OF LITERATURE 
 
Dong-Jiann Huang et al, (2004)119 investigated   possible 
antioxidant and antiproliferative activities of the different extracts 
from sweet potato (Ipomoea batatas [L.] Lam `Tainong 57') 
organs. DPPH staining, total phenolic compounds and flavonoid 
content, DPPH radical, reducing power method, FTC method, 
and cell proliferation were all employed. In the DPPH staining, 
ethanol extract of vein had the highest radical -scavenging 
activity when it was diluted to 6.25 mg dry matter/mL. Among all 
the extracts, the highest amount of total phenolic and flavo noid 
compounds was found in the ethanol extract of vein. In the DPPH 
colorimetric method, it was found that ethanol extract of leaf had 
the highest radical-scavenging activity, followed by water extract 
of vein. In the reducing power activity assay, it was  found that 
the water extract of leaf had the highest reducing power activity, 
followed by ethanol extract of vein. Like phenolic compounds, 
the highest FTC activity was found in the ethanol extract of vein. 
The antiproliferative activities aof sweet potato were studied in 
vitro using human lymphoma NB4 cells, and the following results 
were found: water extract of vein had the highest antiproliferative 
activity with an EC50of 449.6 ± 27.73 µg/mL, followed by water 
extract of storage root, water extract of leaf, ethanol extract of 
storage root, and ethanol extract of leaf. Although the ethanol 
extract of vein showed strong antioxidant activity, it had no 
antiproliferative activity under the experimental conditions 
tested. 
 
Prasanth et al (2010)120 studied invitri cytotoxic and antioxidant 
properties of ethanolic extract of ipomoea 
batatus. The extract showed potent cytotoxicactivity in trypan blu
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e dye exclusion method using DLA cell lines with EC50 value of 
305µg/ml and exhibited a dose dependent decrease in cell count  
for  all  the  concentrations  tested.  The  antioxidant  activity  
was  evaluated  by  DPPH  free  radical method.  
The extract exhibited potent antioxidantactivity with an EC50 of 3
6.5µg/ml. 
 
Wamidh H. Talib et al (2010)121 Reported Forty four extracts 
from sixteen plants used traditionally as anticancer agents  in 
vitro for their antiproliferative activity against Hep-2, MCF-7, and 
Vero cell lines. Plants were fractionated using ethanol, methanol, 
chloroform, n-hexane, distilled water, and butanol. The 
antiproliferative activity was measured by MTT assay. TLC was 
used to identify active fractions. The apoptotic activity of active 
fractions was determined using TUNEL colorimetric assay. 20 of 
these extracts demonstrated significant ant iproliferative activity 
against one or more of the cell lines. These extracts were 
prepared from Ononishirta, Inulaviscosa, Salvia pinardi, 
Verbascumsinaiticumand Ononissicula. Methanol fractions of 
Ononishirta(aerial parts) and Inulaviscosa(flowers) were the 
most active fractions against MCF-7 cells with IC50 of 27.96 and 
15.78 μg/ml respectively and they were less toxic against other 
cell lines. Other extracts showed lower activity against cancer 
cell lines. TLC analysis showed the presence of flavonoids and 
terpenoids in active plants while alkaloids were detected in 
Ononishirta(aerial parts) extracts. Ononishirta(aerial parts) and 
Inulaviscosa(flowers) extracts exerted their antiproliferative 
activity by inducing apoptosis in cancer cell lines.  
 
Seow-Mun Hue et al (2011)122 Evaluated Ipomoea batatas 
(Sweetpotato) is currently ranked sixth in the total world food 
production and are planted mainly for their storage roots. The 
present study was undertaken to evaluate and compare the 
antioxidant properties of the leaf and carotenoids extract from 
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the Ipomoea batatas var. Oren leaves. Total flavonoids in the 
leaf extract was 144.6 ± 40.5 µg/g compared to 114.86 ± 4.35 
µg/g catechin equivalent in the carotenoids extract. Total 
polyphenols in the leaf extracts (3.470 ± 0.024 GAE g/100g DW) 
was slightly higher compared to carotenoids extract (2.994 ± 
0.078 GAE g/100g DW). The carotenoids extract marked a higher 
radical scavenging capacity with the IC50= 491.86 µg/ml 
compared to leaf extract (IC50= 545.39 µg/ml). Concentration -
dependent reducing activity was observed for both extracts. 
Thus, the carotenoids extraction process retained most of the 
antioxidant capacity from the leaves and can be made into 
potential natural yellow dye with antioxidant property.  
Vandana Panda1 et al,(2011)123 Evaluated Ipomoea batatas (L.) 
Lam. from the family Convolvulaceae is the world ’s sixth largest 
food crop. The tubers of Ipomoea batatas commonly known as 
sweet potato are consumed as a vegetable globally. The tubers 
contain high levels of polyphenols such as anthocyanins and 
phenolic acids and vitamins A, B and C, which impart a potent 
antioxidant activity that can translate well to show wound healing 
effects. To check their effects on wound healing, the peels and 
peel bandage were tested on various injury models in rats in the 
present study.  The methanolic extracts of the peels and peel 
bandage of Ipomoea batatas tubers (sweet potato) were 
screened for wound healing by excision and incision wound 
models on Wistar rats. Three types of gel formulations were 
prepared, viz., gel containing 3.0% (w/w) peel extract, gel 
containing 6.0% (w/w) peel extract and gel containing 10% (w/w) 
peel extract. Betadine (5% w/w povidone iodine cream) was used 
as a reference standard. In the incision wound model, Tensile 
strength of the skin was measured. Epithelization time, wound 
contraction, hydroxyproline content of the scab, and ascorbic 
acid and malondialdehyde content of the plasma were 
determined in the excision wound model. Results: In the incision 
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wound model, high tensile strength of the wounded skin was 
observed in animals treated with the peel extract gels and the 
peel bandage when compared with wounded control animals. The 
increase in tensile strength indicates the promotion of collagen 
fibers and that the disrupted wound surfaces are being firmly knit 
by collagen. In the excision wound model, significant wound 
closure was observed on the 4 th day in rats treated with all 
three gel Functional Foods in Health and Disease 2011; 10:403 -
415 Page 404 of 415 formulations when compared with the 
wounded control rats. A significant increase in hydroxyproline 
and ascorbic acid content in the gel -treated animals and a 
significant decrease in malondialdehyde content in the animals 
treated with gel as well as peel bandage was observed when 
compared with the wounded control animals. It may be 
concluded that the peels of Ipomoea batatas tubers possess a 
potent wound healing activity, which may be due to an underlying 
antioxidant mechanism. 
Vandana Panda et al, (2012)124 Conducted studies on peptic 
ulcers occur in that part of the gastrointestinal tract which is 
exposed to gastric acid and pepsin, i.e., the stomach and 
duodenum. Gastric and duodenal ulcers are common pathologies 
that may be induced by a variety of factors such as stress, 
smoking and noxious agents including non-steroidal anti-
inflammatory drugs. Ipomoea batatas tubers (sweet potato) 
contain ample amounts of antioxidants. It has been proven 
already by many scientif ic studies that antioxidants have ulcer 
healing properties. In reference to this, we tried assessing the 
ulcer healing effect of Ipomoea batatas tubers.  The anti -ulcer 
activity of the tubers of Ipomoea batatas (sweet potato) was 
studied in cold stress and aspirin-induced gastric ulcers in 
Wistar rats. Methanolic extracts of Ipomoea batatas tubers (TE) 
at two doses, viz., 400 and 800 mg /kg were evaluated in cold 
stress and aspirin-induced gastric ulcer models using cimetidine 
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and omeprazole respectively as standards. The standard drugs 
and the test drugs were administered orally for 7 days in the cold 
stress model and for 1 day in the aspirin -induced gastric ulcer 
model. Gastroprotective potential, status of the antioxidant 
enzymes {superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GPx) and glutathione reductase(GR)} 
along with GSH, and lipid peroxidation were studied in both 
models. Results: The results of the present study showed that 
TE possessed gastroprotective activity as evidenced by its 
significant inhibition of mean ulcer score and ulcer index a nd a 
marked increase in GSH, SOD, CAT, GPx, and GR levels and 
reduction in lipid peroxidation in a dose dependant manner. 
Conclusion: The present experimental findings suggest that 
tubers of Ipomoea batatas may be useful for treating peptic 
ulcers. 
Yuzhijiao et al (2012)125 The radical scavenging effects by α,α -
diphenyl-β-picrylhydrazyl (DPPH) and superoxide anions of 
anthocyanin extract from purple sweet potato were investigated. 
The antioxidation experiments showed that the reducing power of 
the anthocyanin extract reduced 0.572 at 0.5 mg/ml, while those 
of Lascorbic acid (L-AA) and butylatedhydroxytoluene (BHT) 
reduced 0.460 and 0.121, respectively. They also displayed 
potent antioxidant effects against the DPPH radical and 
superoxide anions radical, showing the IC50 values of 6.94 and 
3.68 μg/ml, respectively. Moreover, this anthocyanin extract also 
could significantly inhibit the formation of lipid peroxidation 
compound. Sixteen kinds of anthocyanins in purple sweet potato 
were detected by high-performance liquid chromatography with 
diode-array detection (HPLC-DAD), and most of the 
anthocyanins were acylated. 
 
Marilena Meira et al (2012)126 ,Approximately 600-700 species 
of Ipomoea, Convolvulaceae, are found throughout tropical and 
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subtropical regions of the world. Several of those species have 
been used as ornamental plants, food, medicines or in religious 
ritual. The present work reviews the traditional uses, chemistry 
and biological activities of Ipomoea species and illustrates the 
potential of the genus as a source of therapeutic agents. These 
species are used in different parts of the world for the treatment 
of several diseases, such as, diabetes, hypertension, dysentery, 
constipation, fatigue, arthritis rheumatism, hydrocephaly,  
meningitis, kidney ailments and inflammations.Some of these 
species showed antimicrobial, analgesic, spasmolitic, 
spasmogenic, hypoglycemic, hypotensive, anticoagulant, anti -infl 
ammatory, psychotomimetic and anticancer activities. Alkaloids, 
phenolics compounds and glycolipids are the most common 
biologically active constituents from these plant extracts . 
 
Adsull et al (2012)127  Microbial diseases remain a major 
challenge for modern science even today. Natural products are 
used as traditional medicines f rom ancient times. They are 
having a great importance in Ayurveda. One of the medicinal 
plant species is Ipomoea carnea belongs to convolvulaceae 
family and fistulosa sub-family. Antimicrobial activity was tested 
against n-hexane, ethyl acetate, acetone, e thanol and acetone 
fraction of acetone extract. The investigation is carried out 
against various gram positive and gram negative bacterial 
strains ( Escherichia coli ATCC – 11246; Staphylococcus aureus 
ATCC – 6538 P; Salmonella typhimurium ATCC – 23564; 
Pseudomonas aeruginosa ATCC – 27853; Proteus vulgaris ATCC 
– 13315; Bacillus cereus ATCC – 11778) . Disc diffusion method 
is employed for the detection of antimicrobial activity. 
Streptomycin was used as standard. The crude acetone extract 
(3) exhibits activity against Proteus vulgaris and Salmonella 
typhimurium, while the crude ethanol extract (4) ellucidates 
antimicrobial activity against Pseudomonous auroginosa  
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RajuAsirvatham et al (2013)128 Conducted  in vitro studies was 
performed to examine the antioxidant and anticancer activities of 
ethanol and aqueous extracts of DroseraindicaL. Methods: 
Different concentrations (5 – 640mcg/ml) of the ethanol (EEDI) 
and aqueous (AEDI) extracts of D.indicaL were used in various 
antioxidant assay methods such as hydroxyl radicals, DPPH, 
super oxide radical scavenging activity, chelating ability of 
ferrous ion, nitric oxide radical inhibition, ABTS and reducing 
power. Ascorbic acid (AA) was used as the standard antioxidant 
for the free radical scavenging assays. Dalton ’s Ascitic 
Lymphoma (DAL) and Ehrlich Ascitic Carcinoma (EAC) cell lines 
were used as the in vitro cancer models for the tryphan blue dye 
and LDH leakage assays, where 5 to 250mcg /ml of both EEDI 
and AEDI were tested. Results: EEDI showed antioxidant 
activities with the minimum IC50 values of 34.8±0.43 mcg/ml in 
scavenging of hydroxyl radical and moreover AEDI showed 
minimum IC50 values of 94.51±0.84 mcg/ml in Fe2+chelating 
assay. EEDI on the reducing power assay and ABTS showed 
higher IC50 than standard AA. IC50 values of AEDI on Fe2+ 
chelating assay and super oxide radical assay was lesser than 
IC50 value of AA. Both extracts at 250mcg/ml dose showed 
remarkable increase in the percentage of dead cancer cells (90% 
by EEDI and 86% by AEDI in DAL model and 89% by EEDI and 
80% by AEDI in EAC model).  
 
Eleazu et al(2013)129 Evaluated The physicochemical 
composition, functional properties, inhibitory actions and energy 
value of the flour of a cream fleshed sweetpotato variety 
(TIS/87/0087) that is high yielding and commercially sold in 
South Eastern Nigeria were investigated using standard 
techniques. The flour was observed to have good functional 
properties with a pH of 5.32±0.01, high percentage moisture 
content, indicative of poor shelf life characteristics and high 
chances of being attacked by microbes, low percentage dry 
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matter, lipid, crude fibre and ash contents but a promising source 
of starch (20.78±0.02%), carotene (5.0±0.04 μg/g), protein 
(2.67±0.59%), carbohydrate (40.77±3.05%), energy 
(179.61±20.97 kcal/100 g), polyphenols, in addition to containing 
significant quantities of  reducing sugar (1.58±0.53%). In 
addition, the methanolic extract of the flour possessed higher 
scavenging activities on 2,2 diphenyl -1-picrylhydrazyl (DPPH) 
radical than standard quercetin. Results show that this sweet 
potato variety has potentials of bio logical properties and could 
have wide utility in food, alcohol and sugar industries. In 
addition, it could serve as a promising source of protein and its 
consumption could be utilized in the management of diseases 
that implicate free radicals. Finally, it  could also be useful as a 
drug binder and disintegrant in pharmaceutical industries.  
 
Zainal Baharum et.al (2014)130 The aims of this study were to 
determine the antioxidant and antiproliferative activity of the 
following Theobroma cacao plant part methanolic extracts: leaf, 
bark, husk, fermented and unfermented shell, pith, root, and 
cherelle. Antioxidant activity was determined using 2,2 -diphenyl-
2-picrylhydrazyl (DPPH), thiobarbituric acid -reactive substances 
(TBARS), and Folin-Ciocalteu assays; diphenyltetrazolium (MTT) 
assay was used to determine antiproliferative activity. The root 
extract had the highest antioxidant activity; its median effective 
dose (EC50) was 358.3 ± 7.0 μg/mL and total phenolic content 
was 22.0 ± 1.1 g GAE/100 g extract as compared to the other 
methanolic plant part extracts. Only the cherelle extract 
demonstrated 10.4% ± 1.1% inhibition activity in the lipid 
peroxidation assay. The MTT assay revealed that the leaf extract 
had the highest antiproliferative activity against MCF-7 cells 
[median inhibitory concentration (IC50) = 41.4 ± 3.3 μg/mL]. 
Given the overall high IC50 for the normal liver cell line WRL-68, 
this study indicates that T. cacao methanolic extracts have a 
cytotoxic effect in cancer cells, but not in normal cells. Planned 
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future investigations will involve the purif ication, identification, 
determination of the mechanisms of action, and molecular assay 
of T. cacao plant extracts. 
 
Marcelia Sugata et.al (2015)131 Purple-fleshed sweet potato 
(PFSP) Tainung 73 possesses high amount of antioxidative 
compounds, such as phenolics, f lavonoid, and anthocyanin. The 
major anthocyanin is cyanidin or/and peonidin and their acylated 
derivatives. Study on the possible properties of PFSP extracts 
showed that these extracts had potent ial anti-inflammatory and 
anticancer activities. Anthocyanin-rich extracts of PFSP TNG 73 
could suppress the production of nitric oxide (NO) and some 
proinflammatory cytokines, such as NFκ -β, TNF-α, and IL-6, in 
LPS-induced macrophage cell. Nevertheless, these extracts 
showed no cytotoxicity effect on macrophage cells. On the other 
hand, these extracts could inhibit the growth of some cancer cell 
lines, such as human breast cancer (MCF-7), gastric cancer 
(SNU-1), and colon adenocarcinoma (WiDr), in concentration- 
and time-dependent manner. After further investigation on 
molecular mechanism, PFSP TNG 73 extracts demonstrated the 
ability to induce apoptosis in MFC-7 cancer cell line through 
extrinsic and intrinsic pathways. Thus, PFSP TNG 73 can be 
used for future application of drugs, nutritional food, and health 
supplement. 
Milind parle et al (2015)132 Sweet potato is an extremely 
versatile and delicious vegetable that posses high nutritional 
value. Sweet potato has been grown in tropical and subtropical 
regions throughout the world, since ancient times. From the 
times immemorial, the whole sweet potato  plant including leaves, 
stem, and tuberous root is used as traditional medicine. 
Nowadays, Sweet potato is preferred over other vegetables due 
to its multifaceted medicinal properties. The medicinal properties 
of sweet potato include anti -cancer, anti-inflammatory, anti-
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diabetic, anti-oxidant, anti-bacterial, anti-fungal, anti-viral, anti-
ulcer, hepatoprotective, wound healing and immunomodulatory 
activities. Sweet potatoes contain magnesium, a crucial mineral, 
which promotes relaxation, calmness and nerve  health. Overall 
objective of this review article is to give a brief knowledge about 
the nutritional value, health benefits, phytochemical composition, 
pharmacological actions and medicinal properties of sweet 
potato. Sweet potato holds first rank (super food) in nutrition 
among vegetables. 
 
HuaJi et al (2015)133 In this study, we selected four different 
color f leshed sweet potatoes, purple- (Jizi 01), red- (Xinong 
431), yellow- (Beijing 553) and white- (Shangshu 19) fleshed 
cultivars as test materials, analyzed nutrient composition, dietary 
fiber content, anthocyanins quantification, and total phenolics 
content, and also measured their total antioxidant activity in four 
different types of sweet potato. In view of differences in f lesh 
color, the nutrient contents of different cultivars appeared to be 
significantly different. Starch contents of Beijing 553 and 
Shangshu 19 were higher, but fat contents were lower than 
others. Protein content of Shangshu 19 was the highest followed 
by Jizi 01 and Xinong 431. In addition, our analysis results 
confirmed that purple fleshed sweet potato possesses much 
higher anthocyanins content than others, even up to 6.23 mg/g 
dry matter. Also, dietary fiber, total phenolics content, and total 
antioxidant capacity of Jizi 01 were significantly higher.  
 
Sucharitha et al (2016)134 A diuretic is any substance that 
promotes the production of urine. This includes forced diuresis. 
There are several categories of diuretics. All diuretics increase 
the excretion of water from bodies, although each class does so 
in a distinct way. Alternatively, an ant diuretic such as 
vasopressin, or ant diuretic hormone, is an agent or drug which 
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reduces the excretion of water in urine. In medicine, diuretics are 
used to treat heart failure, liver cirrhosis, hypertension, 
influenza, water poisoning, and certain kidney diseases. Some 
diuretics, such as acetazolamide, help to make the urine more 
alkaline and are helpful in increasing excretion of substances 
such as aspirin in cases of overdose or poisoning. Diuretics are 
often abused by those with eating disorders, especially bulimics, 
in attempts to lose weight. The antihypertensive actions of some 
diuretics (thiazides and loop diuretics in particular) are 
independent of their diuretic effect. That is, the reduction in 
blood pressure is not due to decreased blood volume resulting 
from increased urine production, but occurs through other 
mechanisms and at lower doses than that required to produce 
diuresis. Indapamide was specifically designed with this in mind, 
and has a larger therapeutic window for hypertension (without 
pronounced diuresis) than most other diuretics. The main 
objective of the present research work is to isolate the bioactive 
molecules and evaluate the diuretic activity of aqueous extract of 
Ipomoea batatasthe phytochemical analysis of aqueous extract 
of Ipomoea batatas root showed the presence of various 
phytochemical constituents such as flavonoids, carbohydrates, 
tannins, phenol. The effect of aqueous extract of root of Ipomoea 
batatas on rats with reference to biochemical changes in serum. 
The group-II (Standard Hydrochlorothiazide 10 ml/kg, p. o) 
animals showed significant (P<0.01) increase in total urine 
volume ml/100 gm/hr (10.44 ml). Whereas animals received AEIB 
significantly (P<0.01) increase in total urine volume ml/100 gm/hr 
(4.44 and 8.06 ml) and significantly (P<0.05) increased total 200 
& 400 mg/kg doses respectively.  The phytochemical studies 
revealed the presence of Carbohydrate, flavonoids, Tannins in 
the AEIB these may be responsible for its pharmacological 
activities. 
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CHAPTER III 
.3. AIM AND OBJECTIVE 
 
Cancer is one of the major problem in worldwide due to life style, 
usage of cancer medications, tobacco usage, lack of proper 
medication, and undefined drug targets. The treatment of cancer 
after so many years of research and experience is still 
unsatisfactory due to certain special characteristics of the cancer 
cell like capacity for uncontrolled proliferation, invasiveness, 
metastasis and dedifferentiation. Such dedifferentiated cancer cells 
can multiply faster when compared to well differentiated cancer 
cells. Several modern drugs are available in the market do not 
fulfill the requirements and also with many side effects. So the 
priority is drugs which minimize the side effects and also required 
chemical entity for the treatment of cancer with specific action. 
Several literatures indicated traditional herbs possessing lesser 
side effects compared to synthetic drugs. The herbal formulations 
which developed from ayurveda, traditional system of Indian 
medicine and its additional system of medicine, has been found to 
have anticancer activity. Ipomoea batatus is a traditionally used 
herb which posses anticancer activity but no scientific validation.. 
Some scientif ic studies show that leaf and root extract of ipomoea 
batatus posses anticancer activity. But there was no literature 
review about anticancer property of the stem available. So the 
present study is an attempt to develop plant based anticancer drug 
which will be lesser side effect.  
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CHAPTER IV 
4. PLAN OF WORK 
 
I. literature Surevey 
 
II. Extraction of dried stem of the Ipomoea batatus by using 
Soxhlet Apparatus. 
 
III. Preliminary phytochemical screening of the ethanolic 
extract of the plant using specific chemical test.  
 
IV. Perform invitro Anti cancer activity will carried out by 
effect of ethanolic extract of the stem of ipomoea batatus 
on MTT assay. 
 
V. Selection of fraction with higher activity.  
 
VI. The Invivo anticancer activity of ethanolic extract of stem 
of Ipomoea batatus  by using DLA Method in mice. 
 
VII. Estimating the effect of ethanolic extract of stem of 
ipomoea batatus on  
 Mean survival time 
 Hemoglobin Count 
 RBC Count 
 WBC Count 
 
VIII. Confirmining the anticancer activity of active constituents 
from literarture. 
 
IX. Conclusion of the work.
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   CHAPTER V 
5. PLANT PROFILE 
 
 
 
5.1. Plant profile 
Kingdom        : plantae  
Subkingdom   : Tracheobionta   
Super division: Spermatophyte  
Division         : Sagnoliophyta  
Class              : Magnoliopsida   
Sub class        : Asteridae 
Order             : Solanales 
Family            : Convolvulaceae 
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Genus             : Ipomoea L.  
Species           : I. batatas (L.) LAM  
Synonyms : 
Kannada    : Genasu. 
Hindi         : Shakarkand / Ratalu. 
Telugu       : Chilakada dumpa. 
Marathi      : Ratala. 
Bengali      : MishtiAlu. 
Malayalam  : Mathura Kizhangu. 
Scientific names 
batatasedulisChoisy             (Kamote (all dialects )  
Convolvulus batatas Linn        (Lapin (if.)  
Convolvulus edulisChoisy      (Pangg-bagun (Sul.) 
Ipomoea batatas (L.)                (Sweet potato (Engl.),  
( Yam (Engl.), 
5.2. Geographical distribution: 
The plant is commonly seen growing in all parts of India, 
Asian and some other European and American countries (9). 
5.3. Chemical constituents of leaf:  
Sweetpotato roots and tops possess a variety of chemical  
compounds relevant to human health. About 80 to 90 % of 
sweetpotato dry matter is made up of carbohydrates, consisting 
mainly of starch (60-70%) and sugars with lesser amounts of 
pectins, hemicelluloses and cellulose. Sweet -potato also contains 
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protein (0.46%-2.93%), dietary fiber (0.49%-4.71%), lipid (0.06%-
0.48%) and ash (0.31%-1.06%). 
It contains essential mineral nutrients such as Ca(117mg), 
(0.56mg),vit E(0.56mg), Fe(1.8mg)/100mg, S, Cu, Zn, P, Mg, Na, K, 
Mn, Al and B.Sweetpotato is also an important source of vitamin A, 
thiamin, riboflavin, niacin, ascorbic acid,β -carotene and many other 
functional compounds. 
Sweetpotato leaves are an excellent source flavonoids with 
antioxidative poly-phenols, with 6 polyphenolic compounds ,15 
anthocyanins and phenol ic acids such as caffeic, 
monocaffeoylquinic (chloro-genic), dicaffeoylquinic and 
tricaffeoylquinic acids, and are superior in this regard to other 
commercial vegetables. 
The another major constituent  flavonoids is 
proanthocyaniins and two or more flavan-3-ol such as catechin, 
epicatechin or gallocatechin. Catechin contains 2 benzene rings to 
be the powerful scavenger(8). 
5.4. Uses Of Ipomoea Batatas 
1 :The young leaves and shoots are sometimes eaten as  greens. 
2 : All parts of the plant are used for animal  fodder. 
3 : Industrial alcolol production.  
4: Sweetpotato leaves used as a vegetable, a tea, in noodles, in 
breads, in    confec-tioneries and as a nutri tional supplement. 
Reported activities of Ipomoea batatas:  
1: Makoto yoshimoto and shoji yahara evaluated the anti -
mutagenic activity of the caffeoylquinic acid derivatives in Ipomoea 
batatas leaf. 
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2: poly phenolics have attracted special attention due to their use 
in oxidative stress which may cause cancer, aging.  
3: Mukesh Nandave, SK Ojha and DS Arya reported that flavonoids 
show anti-thrombotic, anti-ischemic, anti-arrythmic and 
cardioprotective activity by free radical scavenging mechanism.  
4: The leaf extracts also shows anti-bacterial activity, ultraviolet 
protection effect, anti-inflammation and promotion in bowel 
movement. 
Folkloricuse: 
-Crushed leaves applied to boils and acne.   
-Boiled roots used for diarrhea. 
"Ipomoea" comes from the Greek words ipos, which means 
“bind weed” and homoios which means "resembling". When this is 
put together to form "Ipomoea" the direct translation is "resembling 
bindweed". This name makes sense because the sweet potato has 
a twining habit, much like the bindweed. The species name 
"batatas" was originally the Taino name for sweet potato.  
Ipomoea batatas  is a perennial climber growing up to 3 
meters at a fast rate. This is one of those rare plants that are 
grown as a tasty vegetable and a pretty ornamental. Sweet potato  
vine is a vigorous, herbaceous, trailing vine, is native to Central 
America and the Pacific Islands. It offers sweet edible tubers and 
leaves and attractive foliage. 
The leaves are heart-shaped or deeply lobed the colors vary 
from chartreuse, to bronze or purple and can be variegated. The 
funnel-shaped flowers can be pale rosy purple or white. They 
appear when days are long and growing conditions favorable.
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CHAPTER VI 
6. MATERIALS AND METHODS 
 
6.1. Collection of plant 
The stem of Ipomoea batatus were obtained from Department of 
Horticulture, Malappuram and it was authenticated by 
Dr.Raghu.A.V Kerala Forest Research Institute Peechi, Trissur.  
 
6.2. Reagents and Requirements for preliminary extraction 
procedure 
1. Reflux apparatus. 
2.Methanol (Merk Germany) 
3.Dried stem of Ipomoea batatus 
4.Glass ware apparatus 
5.Dessicator 
 
6.3. Extraction of plant material 
 
6.3.1. Extraction 1 
About 100 g of powdered sample was weighed and extracted 
with 500 ml of methanolby reflux method at 24 hours. After the 
reflux, extract was collected dried under reduced pressure, which 
was stored in desiccators. Complete moisture was removed from 
the extract and yield was calculated by using the following formula 
Percentage yield = (B/A) X 100 
Where 
A = Weight of powder 
B = Weight of extract 
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6.3.2. Extraction 2 
About 100 g of dried stem was taken, powdered by a grinder, 
weighed and extracted with 500ml of chloroform by reflux method 
at 24 hours. After the reflux, extract was collected dried under 
reduced pressure which was stored in desiccators in order to 
remove complete moisture from the extract  and yield was 
calculated by using the above formula.  
 
6.3.3. Extraction 3 
About 100g of powdered sample was weighed and extracted 
with 500ml of ethanol by reflux method at 24 hours. After the 
reflux, the extract was collected dried under reduced pressure, 
which was stored in desiccators until complete moisture was 
removed from the extract and yield was calculated by using the 
above formula. 
 
6.4. Preliminary phytochemical screening of the plant  
The ethanol extract of the plant was used for testing preliminary 
phytochemical screening in order to detect major groups.  
 
6.4.1. Test for carbohydrates 
a. Molich’s test: Dissolve small quantity of ethanolic extract of 
Ipomoea batatusseperatlyin a 4ml distilled water and filtered. 
The filterate was subjected to Molisch ’s test. 
b. Fehling’s test: Dissolve a small portion of extract in water 
and treat with Fehling ’s solution. 
c. Phenols test: The extract was spotted on a filter paper. A 
drop of phosphomolybdic acid reagent was added to the spot 
and was exposed to ammonia vapour.  
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6.4.2. Test for flavonoids 
a. Shinoda test: To the 2 to3 ml of extract, a piece of 
magnesium ribbon and 1ml of concentrated HCL was added.  
b. Lead acetate test:  To the 5ml extract 1 ml of lead acetate 
solution was added. 
 
6.4.3. Test for tannins 
a. Braemer ’s test: to the 2 to 2 ml extract, 10% alcoholic ferric 
chloride solution was added. 
 
6.4.4. Test for steroid/terpinoid 
a. Libbermann-Burchardt test: To 1 ml of extract, 1 ml of 
chloroform, 2 to 3 ml of acetic anhydride and 1 to 2 drops of 
concentrated sulphuric acid are added.  
 
 
6.4.5. Test for alkaloids 
a. Draggendrofs test: A drop of extract was spottec on small 
pieces of precoated TLC plate and the plate was sprayed 
with modified Draggendrofs reagent 
b. Hager ’s test: The extract was treated with few ml of Hager ’s 
reagent. 
c. Wagner ’s test: The extract was treated with few ml of 
Wagner ’s reagent. 
 
6.4.6. Test for Glycosides 
a. Legal’s test: Dissolve the extract in 2 ml pyridine, add 
sodium nitroprusside solution 2 ml, and made alkaline with 
sodium hydroxide solution. 
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6.4.7. Test for Saponins 
a. Foam test: 1 ml of extract was diluted with 20ml of distilled 
water and shaken with a graduated cylinder for 15 minutes.  
 
6.4.8. Test for Amino acids 
a. Ninhydrin test: Dissolve a small quantity of extract in few ml 
of water and added 1ml of ninhydrin reagent.  
 
6.4.9. Test for anthraquinones 
a. Borntrager ’s test: About 50mg of powder extract was 
treated with 10% of ferric chloride solution and 1 ml of 
concentrated HCL. The extract was cooled, filtered, and the 
filtrate was shaken with diethyl ether. The ether extract was 
further extracted with strong ammonia.  
 
 
6.4.10. Test for fixed oils and fats  
a. Press small quantity of the petroilum ether extract between 
two filter paper. 
 
The results of the above experiments can be noted as follows.  
 
 If the response to the test is high it can be noted as +++ which 
indicates that the particular group is present as the major class.  
 If the response to the test is average it can be noted as ++ which 
indicates the presence in moderate quantity.  
 If the response is very small note it as + indicating the presence of 
only in traces the response is very small  
 If no response is then negative. 
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6.5. Pharmacological Screening 
6.5.1. Invitro Anticancer Activity 
6.5.2. Mtt Assay: Rapid colorimetric assay for cellular growth and 
survival: application to proliferation and cytotoxicity assays. J 
Immunol Methods 16;65(1-2):55-63 
6.5.3. Tumour Cells 
Tumor cells Ehrlich Ascites Carcinoma (EAC) cells were obtained 
from Amala cancer research center, Trissur, Kerala, India. The 
cells were maintained in vivo in Swiss albino mice by 
intraperitoneal transplantation. EAC cells aspirated from the 
peritoneal cavity of mice were washed with saline and given 
intraperitoneally to develop ascetic tumor.  
 
6.5.2. Mtt Assay (Helacell Lines) 
 
1. For adherent cells, remove the medium and replace it with 100 µL 
of fresh culture medium. For non-adherent cells, centrifuge the 
microplate, pellet the cells, carefully remove as much medium as 
possible and replace it with 100 µL of fresh medium.  
2. Add 10 µL of the 12 mM MTT stock solution (prepared in step 1.1) 
to each well. Include a negative control of 10 µL of the MTT stock 
solution added to 100 µL of medium alone.  
3. Incubate at 37°C for 4 hours. At high cell densities (>100,000 cells 
per well) the incubation time can be shortened to 2 hours.  
4. Add 100 µL of the SDS-HCl solution (prepared in step 1.2) to each 
well and mix thoroughly using the pipette.  
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5. Incubate the microplate at 37°C for 4– hours in a humidified 
chamber. Longer incubations will decrease the sensitivity of the 
assay. 
6. Mix each sample again using a pipette and read abso rbance at 570 
nm. 
6.5.4. Animals 
Male Swiss albino mice weighing 25- 30g were used in the 
present study. All rats were kept at room temperature of 22 -25ºC in 
the animal house. All the animals were followed the internationally 
accepted ethical guidelines for the care of laboratory animals. Prior 
to the experiments, rats were fed with standard food for 1 week in 
order to adapt to the laboratory conditions. All animal procedures 
were performed after approval from the institutional ethics 
committee. The experimental protocol has been approved by 
institutional animal ethics committee, The Karpagam College of 
Pharmacy, Coimbatore 
6.5.5. Acute toxicity study 
Ethanolic extract of Ipomoea batatus stem were studied for acute 
toxicity at doses of 5mg/kg, 50mg/kg, 300mg/kg, 500mg/kg and 
2000mg/kg. As per OECD 420 guideline dose of 2000mg/kg 
showed the toxic symptoms, so according to OECD guideline 420, 
it is considered as a LD50 cutoff value. Doses selected for 
pharmacological studies by fixed dose methods are 250mg/kg  and 
500mg/kg8. 
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6.6.Invivo Anticancer Activity 
The Swiss albino mice (20-25 g) were divided into five 
groups (n=12). Except, Group-I all the animals in DLA group were 
being injected with DLA cells (2×106 cells/mouse, i.p). This was 
marked as day “0”. Group-I was served as normal DLAcontrol  and 
group-II was served as standard group. After 24h, DLA 
transplanted group-III, IV and V were being injected (100, 200 and 
400mg/kg b.w. i.p.) once daily for 12 consecutive days. Group II 
received standard drug 5-Flurouracil (20 mg/kg i.p) for 12 
consecutive days. After administrations of last dose 6 mice from 
each group were kept fasting for 18h and blood was collected by 
direct cardiac puncture for the estimation of haematological 
determination. Rest of animals in each groups were kept alive with 
food and water ad libitum to check the percentage increase in life 
span of the tumor host and also to determine the mean survival 
time (MST).Antitumor activity of MeIB extract was assessed by 
observation of changes with respect to the following parameters  
6.6.1. Antitumour Parameters 
Percentage increase life span The effect of extract on tumor 
growth was monitored by recording the mortality daily for a period 
of 6 weeks and percentage increase in average life span was 
calculated. % ILS = {(life span of treated group/ life span of 
controlled group)-1} X 100 
6.6.2. Body weight analysis 
Body weights of the experimental mice were recorded both in 
the treated and control groups at the beginning of the experiment 
(day 0) and sequentially on every 5th day during the treatment 
period and calculated on 15th day. 
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6.6.3. Changes in food intake 
Feed consumed by 6 animal/cage/week = Total quantity of feed 
offered during that week (gm) – Feed left over on last day of week 
(gm). Feed consumed by individual animal/week = Feed consumed 
by 6 animal per cage per week/6. Feed consumed by individual 
animal/day =Feed consumed by individual animal per week/7.  
6.6.4. Determination of tumor volume and weight 
The mice were dissected and the ascetic fluid was collected from 
the peritoneal cavity. The volume was measured by taking it in a 
graduated centrifuge tube and weight immediately.  
 
6.6.5. Determination of Hematological parameters 
Blood was drawn from each mouse by the retro orbital plexus 
method and the white blood cells (WBC), red blood cells (RBC), 
hemoglobin and protein were determined. Serum preparation of the 
sample blood use to evaluated the biochemical parameters.  
 
6.7. Statistical analysis 
All values were expressed as mean ± SEM. Statistical 
analysis was performed with one way analysis of variance 
(ANOVA) followed by Tukey Kramer multiple comparison tests. P 
value < 0.001 was considered as highly significant and < 0.05 were 
considered significant when compared to control.
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CHAPTER VII 
7. RESULTS AND DISCUSSION 
7.1 Soxhlet Extraction of Ipomoea Batatus  Stem 
 The percentage yield of various extracts viz. petroleum methanol, 
chloroform and ethanol was 23.98%, 35.83%, 20.46%w/w 
respectively 
Table No:1-The percentage yield of stem of Ipomoea batatus stem 
extracts 
 
Figure No: 3  Soxhlet Apparatus 
 
Plant 
Part 
used 
Method of 
Extraction 
Solvents 
Percentage 
Yield 
(%W/W) 
Ipomoea 
batatus 
Dried 
stem 
 
Continuous 
Hot 
percolation 
by Soxhlet 
apparatus 
 
Chloroform 23.98% 
Ethanol 35.83% 
Methanol 20.46% 
 50 
 
. 
7.2 Preliminary phytochemical screening of Ipomoea batatus 
stem extract 
Table No:2 Preliminary phytochemical screening of Ipomoea 
batatus stem extract 
 
Class of  
compounds 
 
Tests performed 
 
Results 
 
Carbohydrates 
 
Molisch ’s test 
Fehling ’s test 
Negetive 
 
Phenols 
 
Phosphomolybdic acid 
test 
Positive 
 
Flavonoids 
Shinoda test 
Lead acetate test 
Positive 
Tannins Braemer ’s test Negetive 
 
Alkaloids 
Wagner ’s 
Mayer ’s 
Draggendrof ’s test 
Positive 
Glycosides Legal ’s test 
Brontranger ’s test 
Positive 
Saponins Foam test Positive 
Sterols Salkowski ’s test Negetive 
Aminoacids Ninhydrin test Negetive 
Terpenoids LibermannBurchardt 
test 
Negetive 
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7.3 Invitro Anticancr Activity 
 
The percentage cell viability is reduced with increase in dose of the 
plant extract. 
Table No: 3 Concentration vs Percentage viability 
Sample Concentration 
(µg/ml) 
MTT assay –HeLa 
% viability 
Control 96.58±0.25 
50 85.26±0.21 
100 62.54±0.34 
150 56.23±0.38 
200 45.23±0.36 
250 42.25±0.40 
 
Figure No.3 Effect Ipomoea batatus stem extract on percentage 
cell viability 
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7.4 Acute Oral Toxicity Studies (OECD 2001) 
After administrating the drug we checked the animals for 15 
days. The parameters checked includes Mortality rate,  Mucous 
membrane, salivation hair falling etc. all the parameters were 
found to be normal. 
Table No.4 - Common Parameters 
Parameters  DLA 
controll 
Standard 
(cyclophos
phamide) 
Extract  
100mg/k
g 
Extract  
200mg/
kg 
Extract  
400mg/
kg 
Skin and fur Normal  Normal  Normal  Normal  Normal  
Eyes  Normal  Normal  Normal  Normal  Normal  
Mucous 
membrane 
Normal  Normal  Normal  Normal  Normal  
Behavioural 
patterns 
Normal  Normal  Normal  Normal  Rapid 
heart 
beat 
COMA Normal  Normal  Normal  Normal  Normal  
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Mortality rate is found to be zero percentage. None of the animals 
died in between the experiment. It shows the extract posses lesser 
side effect and can be used safely.  
Table No: 5 - Mortality rate 
Group Dose 
(mg/kg) 
No.of animals Dose 
difference 
(a) 
 
 
Mortality 
Rate (b) 
  
        
1. 5 6 0  
 
 
 
Zero 
Percentage 
mortality 
rate 
 
 
 
 
 
  
 
2. 
 
50 
 
6 
 
45 
 
3. 
 
300 
 
6 
 
250 
 
4. 
 
2000 
 
6 
 
1750 
LD50 = higher dose ─ Σ (a x b)/ n  Where n = No. of animals in 
each group 
LD50 = 2000─ 0   = 2000 mg / kg  
ED50 = LD50 / 10 = 2000 / 10 = 200mg / kg 
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7.5 Invivo Anticancer Studies 
Table No:7 Effect Of Ipomoea Batatus Stem Extract On Mean 
Survival Time 
 
Figure No: 7- Effect Of Ipomoea Batatus Stem Extract On Mean 
Survival Time 
 
 
 
12
12,2
12,4
12,6
12,8
13
13,2
13,4
13,6
control standard 100mg/kg 200mg/kg 400mg/kg
Mean survival time 
Mean survival time
PARAM
ETERS 
CONTROL 
STANDARD 
(20mg/kg) 
EXTRACT 
(100mg/kg) 
EXTRACT 
(200mg/kg) 
EXTRACT 
(400mg/kg) 
Mean 
survival 
time 
(days) 
14.5±0.14 14±0.14*** 13.8±0.28* 13.1±0.42* 12.9±0.28*** 
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7.6  Effect Of Ipomoea Batatus  Stem Extract On Hemoglobin 
The invivo immunomodulatory activity results have been expressed 
that the ethanolic extract of stem of ipomoea batatus shown 
anticancer activity action when compared to control and positive 
control which is used in dose levels at100, 200 and 400mg/kg  have 
dose dependend anti cancer activity due to constantly decreased 
Hemoglobin. From the figure the anti cancer activity conducted on 
ethanolic extract of fruits of ipomoea batatus on Hemoglobin count 
in mice showed the different drug concentration is less activit y as 
compared to standard drug. After 15 days of analysis the 
Hemoglobin count is less in different drug concentration as 
compared to control drug. 
Table No.8 Effect Of Ipomoea Batatus Stem Extract On Hemoglobin 
Group 
N=6 
Treatment  Dose 
(mg/kg 
body 
weight) 
Hemoglobin count 
Day1 Day 10 Day 15 
Group 
I 
controll 0.6% 9.0±0.13 7.5±0.15 6.6±0.16 
Group 
II 
cyclophosphamide 30 8.9±.018 7.0±0.19 6.1±0.17 
Group 
III 
Ethanolic extract 100 8.2±0.22 6.9±0.21 6.0±0.22 
Group 
IV 
Ethanolic extract 200 7.9±0.26 6.4±0.25 5.9±0.26 
Group 
V 
Ethanolic extract 400 8.5±0.29 7.2±0.30 6.0±0.31 
All values are expressed as mean ± SEM evaluated by ANOVA 
followed by Dunnet ’s t test 
 56 
 
 
Figure No: 9 Effect Of Ipomoea Batatus Stem Extract On 
Hemoglobin Count 
 
Drug concentration vs Hb concentration 
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7.7 Effect Of Ipomoea Batatus  Stem Extract On RBC 
The invivo anticancer activity results have been expressed that the 
ethanolic extract of stem of ipomoea batatus  shown anticancer 
activity, when compared to control and positive control which used 
dose levels at 100,200 and 400mg/kg have dose dependent 
anticancer activity due to constantly decreased RBC cells  
 
Table No:10 Effect Of Ipomoea Batatus Stem Extract On RBC 
Count 
Group 
(N=6) 
Treatment  Dose 
(mg/k
g 
Body 
weight
) 
RBC COUNT 
(x 106/μL) 
Day 1 Day 10 Day 15 
Group I Control  6% 7.5±0.32* 6.3±0.35 6.0±0.30 
Group 
II 
Cyclophos-
phamide 
20 7.2±0.36* 6.1±0.34 5.8±0.29 
Group 
III 
Ethanolic 
 extract 
100 7.5±0.40* 6.2±0.38*** 5.6±0.35 
Group 
IV 
Ethanolic 
 extract 
200 7.4±0.38* 6.1±0.33* 5.5±0.28 
Group 
V 
Ethanolic 
 extract 
400 7.3±0.36* 6.0±0.32** 5.8±0.30 
 
All values are expressed as mean ± SEM evaluated by ANOVA 
followed by Dunnet ’s t test 
 58 
 
 
Figure No:10 Effect Of Ipomoea Batatus  Stem Extract On RBC 
Count 
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7.8 Effect Of Ipomoea Batatus  Stem Extract On WBC 
The invivo anticancer activity results have been expressed that the 
ethanolic extract of stem of ipomoea batatus shown anticancer 
activity, when compared to control and positive control which used 
dose levels at 100,200 and 400mg/kg have dose dependent 
anticancer activity due to constantly decreased WBC cells  
Table No:11 Effect Of Ipomoea Batatus Stem Extract On WBC 
Group  
N=6 
Treatment  Dose 
(mg/k
g 
body 
weight
) 
Total WBC count 
(cells/mm3) 
Day 1 Day 10 Day 15 
Group 
I 
Control  0.6% 10442±8.33 10400±0.004 10343±6.6 
Group 
II 
Cyclophos 
phamide 
30 10900±0.001* 9900±0.006* 5440±9.6* 
Group 
III 
Ethanolic 
extract 
100 9700±0.007* 7250±0.003* 4265±1.00
* 
Group 
IV 
Ethanolic 
extract 
200 9883±16.67* 7183±0.65* 4060±1.00
* 
Grou
p V 
Ethanolic 
extract 
400 10033±21.08
* 
6100±0.004
* 
3900±0.0
09* 
All values are expressed as mean ± SEM evaluated by ANOVA 
followed by Dunnet ’s t test 
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Figure No: 11 Effect Of Ipomoea Batatus Stem Extract On WBC 
 
Drug concentration vs WBC count 
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CHAPTER VIII 
8.SUMMARY AND CONCLUSION 
The preliminary phytochemical investigation revealed the 
compounds present in the stem of Ipomoea batatus. Invitro cancer 
studies were performed using MTT assay with cell lines and found 
that the material possess significant activity. The LD 50 values 
were also determined by doing the assay in various concentrations.  
Herb based drug industry is growing day by day. The destruction of 
natural habitats over exploitation and unsustainable harvest has 
lead to a severe scarcity of raw material. These p roblems have 
adversely affected the quantity of herbal drugs.  
The current work was specific in the field of oncology and revealed 
the fact that the medicinal plants are capable of treating cancer  
The current work revealed that the stem shows significant 
anti-cancer activity. So the production of a herbal formulation for 
the disease will be a boon for the entire pharma industry. The 
identification of chemical compounds present in the stem of 
Ipomoea batatus  which are responsible for the specific activity is 
remaining. In future work I would like to separate the main 
constituents that present in the plant, responsible for the action 
and structure elucidation of those constituents. The present study 
is an attempt to develop novel plant based anti cancer drugs.  
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